Late Breaking Abstract - A phase 3b, randomized controlled trial of gefapixant in recent-onset chronic cough
L. McGarvey (Belfast, Ireland), M. Sher (Largo, United States), Y. Grigorievich Shvarts (Saratov, Russian Federation), S. Lu (Rahway, United States), W. Wu (Rahway, United States), P. Xu (Rahway, United States), J. Schelfhout (Rahway, United States), C. La Rosa (Rahway, United States), A. Martin Nguyen (Rahway, United States), P. Reyfman (Rahway, United States), A. Sadaf Afzal (Rahway, United States), L. McGarvey (Belfast, United Kingdom)
Source: International Congress 2022 – Late-breaking abstracts in airway disease
Session: Late-breaking abstracts in airway disease
Session type: Thematic Poster
Number: 4182
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. McGarvey (Belfast, Ireland), M. Sher (Largo, United States), Y. Grigorievich Shvarts (Saratov, Russian Federation), S. Lu (Rahway, United States), W. Wu (Rahway, United States), P. Xu (Rahway, United States), J. Schelfhout (Rahway, United States), C. La Rosa (Rahway, United States), A. Martin Nguyen (Rahway, United States), P. Reyfman (Rahway, United States), A. Sadaf Afzal (Rahway, United States), L. McGarvey (Belfast, United Kingdom). Late Breaking Abstract - A phase 3b, randomized controlled trial of gefapixant in recent-onset chronic cough. 4182
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|